Emerging and often pro-generics markets are also increasingly tending towards adopting IRP, though often with the proviso that the process should not increase average medicine prices.
To assesses the evolution of international reference pricing (IRP) across 32 countries, from 2006 to 2011.
To assess current influence on innovative drug pricing in the leading five European Union (EU) markets. Both Columbia and Egypt have chosen to include neighbouring and economically similar countries to their reference basket unlike their counterparts that adopted IRP prior to 2006 (refer Chart 1). This trend is further exemplified by China and India who have expressed significant interest in adopting IRP in the future by referencing similar sized economies.
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Finally, given the growing popularity of IRP particularly amongst emerging market regulators, its use as a cost containment tool should be viewed warily. An analysis of the prices of the five aforementioned blockbusters in the EU-5 countries, where Germany and United Kingdom are free priced shows that prices were not necessarily lower in IRP controlled France, Italy and Spain . This is owing to the fact that there still exists room for negotiation in the latter markets.
In Table 1 , the price of Italy, Spain, Germany and UK were compared with that of France. UK consistently had lower prices, not just due to the Euro-Sterling fluctuations but also on account of its indirect price control using the Pharmaceutical Price Regulation Scheme (PPRS) and National Institute of Health and Clinical Excellence's (NICE) cost effectiveness requirements.
Countries globally still rely on EU-5 drug prices when pricing their medicines irrespective of the global economic downturn.
However, newer adopters, particularly emerging markets adopting IRP are also including similar sized economies for price comparison to ensure that they do not pay excessively. This is unlike those emerging markets that adopted IRP prior to 2006, with these countries choosing developed nations as their reference countries in order to promote innovation.
With more emerging markets rolling out IRP, it is notable that in the absence of a set formula that identifies the lowest prices in the reference basket, IRP acts more as a cost harmonisation tool rather than one for cost containment. 
